Management of Patients with Advanced Prostate Cancer: Report from the Advanced Prostate Cancer Consensus Conference 2021

医学 前列腺癌 投票 协商一致会议 德尔菲法 家庭医学 前列腺 疾病 前列腺癌的治疗 癌症 重症监护医学 医学物理学 妇科 内科学 人工智能 政治学 法学 政治 计算机科学
作者
Silke Gillessen,Andrew J. Armstrong,G. Attard,Tomasz M. Beer,Himisha Beltran,Anders Bjartell,Alberto Bossi,Alberto Briganti,Robert G. Bristow,Muhammad Bulbul,Orazio Caffo,Kim N.,Caroline Clarke,Noel W. Clarke,Ian D. Davis,Johann S. de Bono,Ignacio Durán,Ros Eeles,Eleni Efstathiou,Jason A. Efstathiou,Onyeanunam Ngozi Ekeke,Christopher P. Evans,Stefano Fanti,Felix Y. Feng,Karim Fizazi,Mark Frydenberg,Dan George,Martin Gleave,Susan Halabi,Daniel Heinrich,Celesta Higano,Michael S. Hofman,Maha Hussain,Nicholas D. James,Robert J. Jones,Ravindran Kanesvaran,Raja B. Khauli,Laurence Klotz,Raya Leibowitz,C. Logothetis,Fernando C. Maluf,Robin Millman,Alicia K. Morgans,Michael J. Morris,Nicolas Mottet,Hind Mrabti,Declan G. Murphy,Vedang Murthy,William Oh,Piet Ost,Joe M. O’Sullivan,Anwar R. Padhani,Chris Parker,Darren M.C. Poon,Colin C. Pritchard,Danny Rabah,Dana E. Rathkopf,Rob E. Reiter,Mark A. Rubin,Charles J. Ryan,Fred Saad,Juan Pablo Sade,Oliver Sartor,Howard I. Scher,Neal D. Shore,Iwona Skoneczna,Eric J. Small,Matthew R. Smith,Howard R. Soule,Daniel E. Spratt,Cora N. Sternberg,Hiroyoshi Suzuki,Christopher J. Sweeney,Matthew R. Sydes,Mary‐Ellen Taplin,Derya Tilki,Bertrand Tombal,Levent Türkeri,Hiroji Uemura,Hirotsugu Uemura,Inge M. van Oort,Kosj Yamoah,Dingwei Ye,A. Zapatero,Aurelius Omlin
出处
期刊:European Urology [Elsevier BV]
卷期号:82 (1): 115-141 被引量:71
标识
DOI:10.1016/j.eururo.2022.04.002
摘要

Innovations in treatments, imaging, and molecular characterisation in advanced prostate cancer have improved outcomes, but various areas of management still lack high-level evidence to inform clinical practice. The 2021 Advanced Prostate Cancer Consensus Conference (APCCC) addressed some of these questions to supplement guidelines that are based on level 1 evidence.To present the voting results from APCCC 2021.The experts identified three major areas of controversy related to management of advanced prostate cancer: newly diagnosed metastatic hormone-sensitive prostate cancer (mHSPC), the use of prostate-specific membrane antigen ligands in diagnostics and therapy, and molecular characterisation of tissue and blood. A panel of 86 international prostate cancer experts developed the programme and the consensus questions.The panel voted publicly but anonymously on 107 pre-defined questions, which were developed by both voting and non-voting panel members prior to the conference following a modified Delphi process.The voting reflected the opinions of panellists and did not incorporate a standard literature review or formal meta-analysis. The answer options for the consensus questions received varying degrees of support from panellists, as reflected in this article and the detailed voting results reported in the Supplementary material.These voting results from a panel of experts in advanced prostate cancer can help clinicians and patients to navigate controversial areas of management for which high-level evidence is scant. However, diagnostic and treatment decisions should always be individualised according to patient characteristics, such as the extent and location of disease, prior treatment(s), comorbidities, patient preferences, and treatment recommendations, and should also incorporate current and emerging clinical evidence and logistic and economic constraints. Enrolment in clinical trials should be strongly encouraged. Importantly, APCCC 2021 once again identified salient questions that merit evaluation in specifically designed trials.The Advanced Prostate Cancer Consensus Conference is a forum for discussing current diagnosis and treatment options for patients with advanced prostate cancer. An expert panel votes on predefined questions focused on the most clinically relevant areas for treatment of advanced prostate cancer for which there are gaps in knowledge. The voting results provide a practical guide to help clinicians in discussing treatment options with patients as part of shared decision-making.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
gentle发布了新的文献求助10
刚刚
wspqbs关注了科研通微信公众号
1秒前
xiang完成签到,获得积分10
2秒前
erlangenbio完成签到,获得积分10
2秒前
2秒前
深情安青的应助被杜欣悦采纳,获得10
3秒前
4秒前
modoun完成签到,获得积分10
5秒前
iNk的应助被ladywerwer采纳,获得10
6秒前
apricity199的应助被淘宝叮咚采纳,获得10
7秒前
吃不饱完成签到 ,获得积分10
8秒前
空城完成签到 ,获得积分20
10秒前
10秒前
ladywerwer完成签到,获得积分10
11秒前
11秒前
11秒前
wspqbs发布了新的文献求助30
13秒前
13秒前
风中巧凡完成签到,获得积分10
14秒前
bqys发布了新的文献求助10
14秒前
jean完成签到,获得积分10
15秒前
哇啦发布了新的文献求助10
15秒前
16秒前
研友_VZG7GZ的应助被O基米德采纳,获得10
16秒前
笑点低薯片完成签到,获得积分10
19秒前
小马甲的应助被调皮钧采纳,获得10
19秒前
雅2018完成签到 ,获得积分10
20秒前
20秒前
能干发卡完成签到,获得积分10
20秒前
zqq完成签到,获得积分10
20秒前
郗超悦完成签到,获得积分10
21秒前
SciGPT的应助被学术小白采纳,获得10
21秒前
英姑的应助被笑点低薯片采纳,获得10
22秒前
夏弱完成签到,获得积分10
23秒前
高级的百香果完成签到,获得积分10
24秒前
April完成签到,获得积分10
24秒前
JamesPei的应助被Alexlovar采纳,获得30
25秒前
25秒前
青山白鸟完成签到 ,获得积分10
26秒前
26秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
八旗制度の研究 600
Boundaries and Bodhisattvas 500
高分子基功能界面水蒸发材料与应用研究 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8181839
求助须知:如何正确求助?哪些是违规求助? 9571584
关于积分的说明 21818707
捐赠科研通 7778124
什么是DOI,文献DOI怎么找? 3433524
关于科研通互助平台的介绍 2557710
邀请新用户注册赠送积分活动 2479621